These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 9057699)

  • 1. Protection of mice against visceral leishmaniasis by immunization with promastigote antigen incorporated in liposomes.
    Ali N; Afrin F
    J Parasitol; 1997 Feb; 83(1):70-5. PubMed ID: 9057699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of partial protection against Leishmania donovani by promastigote antigens in negatively charged liposomes.
    Afrin F; Anam K; Ali N
    J Parasitol; 2000 Aug; 86(4):730-5. PubMed ID: 10958448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non PC liposome entrapped promastigote antigens elicit parasite specific CD8+ and CD4+ T-cell immune response and protect hamsters against visceral leishmaniasis.
    Sharma SK; Dube A; Nadeem A; Khan S; Saleem I; Garg R; Mohammad O
    Vaccine; 2006 Mar; 24(11):1800-10. PubMed ID: 16310900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice.
    Mazumdar T; Anam K; Ali N
    Vaccine; 2004 Mar; 22(9-10):1162-71. PubMed ID: 15003644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of liposome based antigen delivery systems for protection against Leishmania donovani.
    Bhowmick S; Mazumdar T; Sinha R; Ali N
    J Control Release; 2010 Jan; 141(2):199-207. PubMed ID: 19818373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced efficacy and immunogenicity of 78kDa antigen formulated in various adjuvants against murine visceral leishmaniasis.
    Nagill R; Kaur S
    Vaccine; 2010 May; 28(23):4002-12. PubMed ID: 20093205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isotype profiles of Leishmania donovani-infected BALB/c mice: preferential stimulation of IgG2a/b by liposome-associated promastigote antigens.
    Afrin F; Ali N
    J Parasitol; 1998 Aug; 84(4):743-8. PubMed ID: 9714204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pure protein from Leishmania donovani protects mice against both cutaneous and visceral leishmaniasis.
    Rachamim N; Jaffe CL
    J Immunol; 1993 Mar; 150(6):2322-31. PubMed ID: 8450215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leishmanial antigens in liposomes promote protective immunity and provide immunotherapy against visceral leishmaniasis via polarized Th1 response.
    Bhowmick S; Ravindran R; Ali N
    Vaccine; 2007 Aug; 25(35):6544-56. PubMed ID: 17655984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of cellular and humoral responses by autoclaved and heat-killed antigen of Leishmania donovani in experimental visceral leishmaniasis.
    Nagill R; Mahajan R; Sharma M; Kaur S
    Parasitol Int; 2009 Dec; 58(4):359-66. PubMed ID: 19638322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of phospholipid composition on the adjuvanticity and protective efficacy of liposome-encapsulated Leishmania donovani antigens.
    Mazumdar T; Anam K; Ali N
    J Parasitol; 2005 Apr; 91(2):269-74. PubMed ID: 15986599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination with Leishmania soluble antigen and immunostimulatory oligodeoxynucleotides induces specific immunity and protection against Leishmania donovani infection.
    Tewary P; Pandya J; Mehta J; Sukumaran B; Madhubala R
    FEMS Immunol Med Microbiol; 2004 Oct; 42(2):241-8. PubMed ID: 15364110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-coding pDNA bearing immunostimulatory sequences co-entrapped with leishmanial antigens in cationic liposomes elicits almost complete protection against experimental visceral leishmaniasis in BALB/c mice.
    Mazumder S; Ravindran R; Banerjee A; Ali N
    Vaccine; 2007 Dec; 25(52):8771-81. PubMed ID: 18031874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvanticity and protective immunity elicited by Leishmania donovani antigens encapsulated in positively charged liposomes.
    Afrin F; Ali N
    Infect Immun; 1997 Jun; 65(6):2371-7. PubMed ID: 9169776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acylated and deacylated saponins of Quillaja saponaria mixture as adjuvants for the FML-vaccine against visceral leishmaniasis.
    Oliveira-Freitas E; Casas CP; Borja-Cabrera GP; Santos FN; Nico D; Souza LO; Tinoco LW; da Silva BP; Palatnik M; Parente JP; Palatnik-de-Sousa CB
    Vaccine; 2006 May; 24(18):3909-20. PubMed ID: 16556475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination against murine cutaneous leishmaniasis by using Leishmania major antigen/liposomes. Optimization and assessment of the requirement for intravenous immunization.
    Kahl LP; Scott CA; Lelchuk R; Gregoriadis G; Liew FY
    J Immunol; 1989 Jun; 142(12):4441-9. PubMed ID: 2786033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serodiagnostic and immunoprophylactic potential of a 78kDa protein of Leishmania donovani of Indian origin.
    Mukherjee M; Bhattacharyya A; Duttagupta S
    Med Sci Monit; 2002 Apr; 8(4):BR117-22. PubMed ID: 11951057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leishmania donovani recombinant iron superoxide dismutase B1 protein in the presence of TLR-based adjuvants induces partial protection of BALB/c mice against Leishmania major infection.
    Daifalla NS; Bayih AG; Gedamu L
    Exp Parasitol; 2012 Jul; 131(3):317-24. PubMed ID: 22580023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.
    Melby PC; Yang J; Zhao W; Perez LE; Cheng J
    Infect Immun; 2001 Aug; 69(8):4719-25. PubMed ID: 11447143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination with liposomal leishmanial antigens adjuvanted with monophosphoryl lipid-trehalose dicorynomycolate (MPL-TDM) confers long-term protection against visceral leishmaniasis through a human administrable route.
    Ravindran R; Maji M; Ali N
    Mol Pharm; 2012 Jan; 9(1):59-70. PubMed ID: 22133194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.